Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22188545 | 0.87 | PKM (0.45) | CYP4F2CYP4A11USP2SMN1; SMN2PKM | |
| SCHEMBL2474730 | 0.87 | USP2 (0.40) | CYP4F2CYP4A11USP2SMN1; SMN2MEN1 | |
| SCHEMBL1281827 | 0.86 | USP2 (0.39) | CYP4F2CYP4A11USP2SMN1; SMN2MEN1 | |
| SCHEMBL550598 | 0.86 | KMT2A (0.49) | CYP4F2CYP4A11MEN1KMT2ANPC1 | |
| SCHEMBL963907 | 0.84 | USP2 (0.47) | CYP4F2CYP4A11USP2SMN1; SMN2MEN1 | |
| SCHEMBL16101462 | 0.83 | USP2 (0.41) | CYP4F2CYP4A11USP2SMN1; SMN2MEN1 | |
| SCHEMBL7309006 | 0.83 | USP2 (0.43) | CYP4F2CYP4A11USP2SMN1; SMN2MEN1 | |
| SCHEMBL390461 | 0.82 | USP2 (0.42) | CYP4F2CYP4A11USP2SMN1; SMN2MEN1 | |
| SCHEMBL20565162 | 0.82 | USP2 (0.42) | CYP4F2CYP4A11USP2SMN1; SMN2MEN1 | |
| SCHEMBL606159 | 0.82 | USP2 (0.42) | CYP4F2CYP4A11USP2SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193207-B2 | Lactam compounds and methods of using the same | INCYTE CORPORATION (US) | 2012-06-05 | — | — | US | disclosed |
| US-20070129345-A1 | Lactam compounds and methods of using the same | INCYTE CORPORATION | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129345-A1 | Lactam compounds and methods of using the same | HSD11B1, HSD17B11, HSD17B1 | CYP4F2 209/4885CYP4A11 31/4885USP2 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.